Skip to main content

Table 2 Progression-free survival in locally advanced rectal cancer

From: Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer

 

HR1

95 % CI

p-value

ΔNACT

 

0.994

(0.990–0.999)

0.01

Age

 

0.953

(0.914–0.993)

0.02

TN stage

T2–3

   

T4

2.71

(1.17–6.27)

0.02

 

N0–1

   

N2

1.22

(0.449–3.30)

0.70

Baseline CEA level

≤ULN

   

>ULN

1.85

(0.799–4.29)

0.15

ypTN

ypT0–2

   

ypT3–4

6.10

(2.22–16.7)

<0.001

 

ypN0

   

ypN1–2

2.84

(1.20–6.70)

0.02

TRG score

TRG1–2

   

TRG3–5

3.00

(1.27–7.08)

0.01

  1. Adjusted hazard ratio (HR) with 95 % confidence interval (CI) was calculated by univariate Cox regression analysis for each of the indicated variables
  2. ΔNACT paired serum sample measurements of carbonic anhydrase IX following neoadjuvant induction chemotherapy versus baseline, CEA carcinoembryonic antigen, ULN upper limit of normal, TRG tumour regression grade
  3. 1: HR less than 1 indicates that patients had higher probability of favourable progression-free survival
Back to article page